Ligand Pharmaceuticals (LGND) Income from Continuing Operations (2010 - 2026)
Ligand Pharmaceuticals (LGND) posted Income from Continuing Operations of 13345000.0 for Q1 2026, down 129.8% sequentially from 44784000.0 in Q4 2025, and up 68.56% YoY from 7916885.77 in Q1 2025.
Ligand Pharmaceuticals (LGND) Income from Continuing Operations (2010 - 2026) Analysis & Trends
Ligand Pharmaceuticals has reported Income from Continuing Operations for 17 years, with the latest figure at 13345000.0 in Q1 2026.
- Quarterly Income from Continuing Operations rose 68.56% year-over-year to 13345000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 153559000.0 (up 215.79% YoY) and the FY2025 annual result came in at 124453000.0, up 3186.63% from the prior year.
- Income from Continuing Operations fell to 13345000.0 in Q1 2026 per LGND's latest filing, from 44784000.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 117273000.0 in Q3 2025 and troughed at 51911000.0 in Q2 2024.
- A 5-year average of 9157411.76 and a median of 2290000.0 in 2023 frame the typical range for Income from Continuing Operations.
- The sharpest annual moves came in 2024 and 2025: Income from Continuing Operations slumped 2366.86% in 2024, then soared 1735.15% in 2025.
- Over 5 years, Income from Continuing Operations stood at 14534000.0 in 2022, then soared by 225.14% to 18188000.0 in 2023, then plunged by 270.93% to 31088000.0 in 2024, then surged by 244.06% to 44784000.0 in 2025, then tumbled by 129.8% to 13345000.0 in 2026.
- According to Business Quant data, Income from Continuing Operations over the past three periods registered 13345000.0, 44784000.0, and 117273000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 482.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,096.02 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Ligand Pharmaceuticals | 5.87 Bn | 4.51 Bn | 60.48 Mn | 48.51 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 48.51 Mn |
| Mar 31, 2026 | -13.35 Mn |
| Dec 31, 2025 | 44.78 Mn |
| Sep 30, 2025 | 117.27 Mn |
| Jun 30, 2025 | 4.85 Mn |
| Mar 31, 2025 | -42.45 Mn |
| Dec 31, 2024 | -31.09 Mn |
| Sep 30, 2024 | -7.17 Mn |
| Jun 30, 2024 | -51.91 Mn |
| Mar 31, 2024 | 86.14 Mn |
| Dec 31, 2023 | 18.19 Mn |
| Sep 30, 2023 | -10.27 Mn |
| Jun 30, 2023 | 2.29 Mn |
| Mar 31, 2023 | 43.61 Mn |
| Dec 31, 2022 | -14.53 Mn |
| Sep 30, 2022 | 9.65 Mn |
| Jun 30, 2022 | 12.60 Mn |
| Mar 31, 2022 | -12.93 Mn |
| Dec 31, 2021 | 13.80 Mn |
| Sep 30, 2021 | 13.72 Mn |